<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00658125</url>
  </required_header>
  <id_info>
    <org_study_id>06-0095-B</org_study_id>
    <nct_id>NCT00658125</nct_id>
  </id_info>
  <brief_title>Deep Brain Stimulation (DBS) for Alzheimer's Disease</brief_title>
  <official_title>Modulation of Cognitive Function Using Electrical Brain Stimulation in Patients With Early Alzheimer Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Alzheimer disease (AD) is a debilitating brain disorder that affects over 4.75
      million people in the US and Canada. People with AD have difficulty remembering general facts
      and previously experienced autobiographical events. Animal and human research demonstrates
      that this type of memory depends on neural function within specific brain areas, and that it
      may be possible to enhance memory with electrical stimulation of these brain areas. We have
      recently shown that deep brain stimulation (DBS) of a brain area called the fornix enhances
      memory in a human.

      Hypotheses: We hypothesize that fornix DBS will safely enhance memory in early AD patients by
      activating memory circuits in the brain.

      Methods: Six early AD patients will take part in a phase I clinical study over a 1-year
      period. The study involves bilateral fornix DBS implantation, detailed neuropsychological and
      neurological testing, and brain imaging to detect alterations in brain activity induced by
      stimulation. These assessments will occur one month before surgery, then again at one month,
      6 months, and 12 months after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2007</start_date>
  <completion_date type="Actual">June 30, 2010</completion_date>
  <primary_completion_date type="Actual">June 30, 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>memory performance on neuropsychological tests</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bilateral fornix DBS implantation,</intervention_name>
    <description>Fornix DBS for Alzheimer Disease</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>DBS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 40 to 80 years old, who

          -  Satisfy the diagnostic criteria for probable AD,

          -  Have received the diagnosis of AD within the past 2 years,

          -  Have a CDR of 0.5 or 1.0, and

          -  Score between 20 and 28 on the Mini Mental State Examination

        Exclusion Criteria:

          -  Pre-existing structural brain abnormalities,

          -  Other neurologic or psychiatric diagnoses, or

          -  Medical comorbidities that would preclude them from undergoing surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian W Laxton, MD</last_name>
    <role>Study Director</role>
    <affiliation>Toronto Western Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andres M Lozano, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto Western Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Tang-Wai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto Western Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Hamani C, McAndrews MP, Cohn M, Oh M, Zumsteg D, Shapiro CM, Wennberg RA, Lozano AM. Memory enhancement induced by hypothalamic/fornix deep brain stimulation. Ann Neurol. 2008 Jan;63(1):119-23. doi: 10.1002/ana.21295.</citation>
    <PMID>18232017</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 9, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Andres M. Lozano</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

